Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 inhibitor plus rosuvastatin maintenance after ASCT in DLBCL
ChiCTR2500115485Phase 2Recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Dec 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rosuvastatin in diffuse large B-cell lymphoma (DLBCL), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Progression-free survival at 18 months. Started Dec 2025; status: recruiting.
02
Drugs
rosuvastatin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2500115485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115485.